Your Questions About Hantavirus, Answered

For most hantavirus strains — including Sin Nombre virus in North America — person-to-person transmission has never been documented. The exception is Andes virus in South America, which has been confirmed to spread between people in close contact, including household members and sexual partners. The 2026 cruise ship outbreak further confirmed this capacity. The CDC recommends standard infection control precautions for those in contact with confirmed Andes virus patients. CDC: Hantavirus

The incubation period for HPS is typically 1 to 8 weeks, with most cases developing symptoms within 2 to 4 weeks of exposure. HFRS has a similar incubation of 2 to 4 weeks. Because the window is so wide, it can be difficult to pinpoint the exact exposure event. The CDC emphasizes that any rodent contact within the preceding 8 weeks is clinically relevant exposure history. CDC: Hantavirus

There is no approved antiviral specific to hantavirus. Treatment is entirely supportive — maintaining breathing (sometimes requiring mechanical ventilation or ECMO) and blood pressure. Ribavirin has shown some benefit for HFRS when given early but is not proven effective for HPS. Survival depends heavily on early recognition and prompt ICU admission.

It depends on the strain and quality of medical care available. Sin Nombre virus (HPS) has a case fatality rate of approximately 38% in the United States. Andes virus is comparable. HFRS strains vary widely — Hantaan virus (Asia) has up to about 15% mortality, while Puumala virus (Europe, "nephropathia epidemica") is generally mild with less than 1% mortality.

Captive-bred laboratory or pet rodents (rats, mice, hamsters) sold by reputable U.S. vendors are not known carriers of hantavirus and pose no risk. The danger comes exclusively from wild rodents — particularly deer mice, cotton rats, white-footed mice, and rice rats depending on your region.

No vaccine for hantavirus is licensed in the United States or Europe, and none exists anywhere for the viruses that cause disease in the Americas. Inactivated whole-virus vaccines against Hantaan or Seoul virus are licensed for human use in the Republic of Korea and in China, though published reviews state that their protective efficacy is uncertain. In the U.S., DNA vaccine candidates for Andes virus and for Hantaan/Puumala have completed Phase 1 and Phase 2 immunogenicity studies and none has progressed further — with roughly thirty U.S. cases a year, no efficacy trial can accumulate enough events to measure protection.

The primary carrier of Sin Nombre virus is the deer mouse (Peromyscus maniculatus), found across most of North America. Other carriers include the cotton rat (Sigmodon hispidus) in the Southeast, the white-footed mouse (Peromyscus leucopus) in the East, and the rice rat (Oryzomys palustris) in the Southeast coastal areas.

Never sweep or vacuum droppings — this aerosolises virus particles. The CDC-recommended cleanup protocol calls for: ventilating the space for at least 30 minutes before entering; wearing rubber gloves and an N95 respirator; spraying droppings and nesting material with a 10% bleach solution and leaving for 5–10 minutes; wiping up with paper towels and sealing in a plastic bag; and disinfecting the area thoroughly before removing PPE. CDC cleanup protocol

Yes — specifically through aerosols created when dried rodent urine, feces, or nesting material is disturbed. It is not airborne the way COVID-19 or flu spreads via respiratory droplets from infected people. The exception is Andes virus in South America, which can spread person-to-person.

New Mexico, Colorado, Arizona, and California have the highest cumulative case counts since 1993. Washington, Texas, Montana, Idaho, and Wyoming also report regular cases. The rural West and Southwest account for the vast majority of U.S. HPS cases. The eastern U.S. has far fewer cases, though hantavirus rodent reservoirs exist across most of North America.

Hantavirus is rare. The CDC has recorded 890 hantavirus disease cases in the United States through 2023 — an average of roughly 30 per year (historically ranging from about 10 to 48) since surveillance began in 1993. While uncommon, HPS is severe and frequently fatal — warranting serious prevention measures for people in endemic areas.

Dogs and cats do not become infected with hantavirus and cannot spread it directly to people. However, they may bring infected rodents, carcasses, or contaminated materials into homes. In high-risk areas, discourage pets from hunting rodents and inspect them before allowing them back indoors.

In cool, dark, humid indoor environments (closed cabins, basements, storage areas), hantavirus in dried rodent excreta can survive for days to weeks. Direct sunlight inactivates the virus within hours. A 10% bleach solution kills it in minutes. This is why closed, dark spaces with rodent activity are the highest-risk environments for infection.

Yes. Hantavirus Pulmonary Syndrome has a ~38% case fatality rate in the United States even with modern ICU care. The cardiopulmonary phase can develop within days and become fatal within 24–48 hours. Early recognition and immediate ICU admission are the most important survival factors.

You cannot self-diagnose hantavirus. Diagnosis requires blood testing (PCR or IgM antibody detection) at a specialized laboratory in a hospital setting. According to CDC diagnostic guidance, potential rodent exposure in the past 8 weeks combined with compatible symptoms (fever, severe muscle aches) is what prompts clinical consideration of hantavirus testing. Detailed exposure history is the key information clinicians need. There is no home test. CDC: Hantavirus

Yes. A 10% bleach solution (1 part household bleach to 9 parts water) is the CDC's recommended disinfectant for hantavirus and kills it within minutes. Other effective options include 70% isopropyl alcohol and EPA-registered disinfectants labeled for enveloped viruses (such as Lysol).

It is possible, though the greater risk is inhaling disturbed dried feces, urine, or nesting material rather than the carcass itself. The CDC recommends wearing rubber or nitrile gloves when handling dead rodents, double-bagging the carcass before disposal, and washing hands thoroughly afterward. CDC cleanup guidance

Yes. Children can contract hantavirus the same way adults do — by inhaling aerosolized particles or through direct contact with contaminated materials. Children in rural areas who play in barns, sheds, or old buildings should be supervised and kept away from rodent-infested spaces.

Reinfection with the same hantavirus strain is thought to be unlikely due to the immune response from initial infection. However, immunity from one strain does not necessarily protect against other strains. Confirmed reinfection cases are extremely rare in the medical literature.

No. Hantavirus and COVID-19 are caused by entirely different viruses with different transmission routes. Hantavirus in North America comes from rodent excreta — not from other people. Both can cause severe respiratory illness, but early symptoms, treatment, and prevention are very different. Neither flu antivirals nor COVID treatments address hantavirus.

Yes. RVs, camper vans, and trailers stored over winter are prime rodent habitat — warm, enclosed, and often with food remnants. The CDC recommends ventilating stored vehicles for at least 30 minutes before use, inspecting for rodent signs (droppings, gnaw marks, nesting material), and cleaning any contaminated areas with a bleach solution before entry. CDC cleanup guidance

The CDC emphasizes that detailed rodent exposure history — including timing, location, and nature of any contact in the preceding 8 weeks — is the key clinical information that prompts consideration of hantavirus testing. Providing specifics about recent activity (cleaning a cabin, working in a barn, camping in endemic areas) helps clinicians evaluate possible cases. The CDC notes that hantavirus may not be in a clinician's initial differential; comprehensive exposure history is therefore essential. CDC: Hantavirus

For Hantavirus Pulmonary Syndrome (HPS) in the United States, approximately 62% of patients survive — a case fatality rate of about 38%. In the largest published series, roughly 60–66% of the most severe HPS patients placed on ECMO survived, despite a predicted mortality near 100% (Dietl 2008). For HFRS strains, survival varies: Puumala virus (Europe) has under 1% mortality; Hantaan virus (Asia) has up to about 15% mortality.